GlassScriptPhysician profile
Elena Mcginty
NPI 1386281533
$28,044.65
in general payments reported to CMS, 2019-2025
28 companies · $9,235 in 2025
The $9,235 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,287 · 2022: $3,661 · 2023: $7,325 · 2024: $5,537 · 2025: $9,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $126 · Consulting Fee: $115 · Education: $19.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,086.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,750.00 |
| Travel and Lodging | $126.14 |
| Consulting Fee | $115.00 |
| Education | $19.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,255.76 | 2021-2025 | |
| Alkermes, INC. | $2,268.81 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,519.34 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,397.98 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $1,331.47 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,136.90 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $889.62 | 2021-2025 | Ingrezza |
| Corium, LLC | $832.10 | 2022-2025 | Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $802.70 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $682.35 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $453.56 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $429.55 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $385.39 | 2021-2023 | Invega Sustenna |
| Bausch Health US, LLC | $374.98 | 2021-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $340.58 | 2021-2025 | Trintellix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $314.19 | 2022-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $146.86 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $143.61 | 2022-2025 | Adzenys Xr-Odt |
| Braeburn INC. | $81.28 | 2024 | Brixadi |
| Acadia Pharmaceuticals INC | $50.93 | 2022-2025 | Nuplazid |
| Astellas Pharma US INC | $46.60 | 2024 | Veozah |
| Eisai INC. | $40.79 | 2021-2022 | |
| Indivior INC. | $27.56 | 2025 | Sublocade |
| Almatica Pharma LLC | $25.52 | 2021-2022 | |
| Livanova USA, INC. | $22.24 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.98 | 2025 | Rejoyn |
| Ironshore Pharmaceuticals INC. | $12.81 | 2023 | Jornay Pm |
| Tris Pharma INC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Mcginty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.